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Reconstitution of human telomerase activity in vitro
Tara L. Beattie*, Wen Zhou†, Murray O. Robinson† and Lea Harrington*
Telomerase is a ribonucleoprotein enzyme complex
that adds single-stranded telomere DNA to
chromosome ends [1]. The RNA component of
telomerase contains the template for telomeric DNA
addition and is essential for activity [1,2]. Telomerase
proteins have been identified in ciliates, yeast and
mammals [3–12]. In Saccharomyces cerevisiae, the
Est2 protein is homologous to the 123 kDa reverse
transcriptase subunit of Euplotes telomerase, and is
essential for telomerase activity [8]. In humans,
telomerase activity is associated with the telomerase
RNA hTR [13], the telomerase RNA-binding protein
TP1/TLP1 [5,12] and the TP2 protein encoded by the
human EST2 homolog [12] (also known as TRT1, hEST2
or TCS1 [9–11]). The minimal complex sufficient for
activity is, however, unknown. We have reconstituted
human telomerase activity in reticulocyte lysates and
find that only exogenous hTR and TP2 are required for
telomerase activity in vitro. Recognition of telomerase
RNA by TP2 was species specific, and nucleotides
10–159 of hTR were sufficient for telomerase activity.
Telomerase activity immunoprecipitated from the
reticulocyte lysate contained hTR and recombinant TP2.
Substitution of conserved amino acid residues in the
reverse transcriptase domain of TP2 completely
abolished telomerase activity. We suggest that TP2 and
hTR might represent the minimal catalytic core of
human telomerase.
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Results and discussion
Reconstitution of telomerase activity using hTR RNA and
recombinant TP2 protein
The reconstitution of ciliate and human telomerases has
been characterized using recombinant telomerase RNA
in the presence of partially purified, micrococcal-nucle-
ase-treated lysates [1,14], but the minimal protein com-
position of active human telomerase remains unknown.
Recently, we have functionally characterized TP2 as the
catalytic subunit of human telomerase in human cells
[12], and sought to determine whether recombinant TP2
could reconstitute human telomerase activity in vitro. We
found that rabbit reticulocyte lysates did not contain
endogenous telomerase activity (Figure 1a, lane 2), but
telomerase activity could be detected when purified hTR
RNA (nucleotides 10–530 of the hTR gene [13]) was
Figure 1
Human TP2 protein and telomerase RNA reconstitute telomerase
activity in reticulocyte lysates. (a) Results of telomerase assays.
Lane 1, 5 µg HeLa cell lysate; lane 2, no template cDNA added; lane 3,
TP2 cDNA only (0.1 µg translated in a 10 µl reticulocyte reaction);
lanes 4–16, TP2 cDNA in the presence of increasing concentrations
of the indicated RNA species (0.001 µg, 0.01 µg, or 0.1 µg RNA per µl
lysate): lanes 4–6, hTR RNA; lane 7, the same reaction in lane 6,
preincubated with ribonuclease A (RNAse A) prior to the telomerase
assay; lanes 8–10, antisense human telomerase RNA, αhTR;
lanes 11–13, transfer RNA, tRNA; lanes 14–16, full-length sense
mouse telomerase RNA, mTR; lane 17, 0.1 µg hTR RNA only. (b) Each
of the in vitro translation mixtures (approximately 2 µl) in (a) containing
0.001 µg/µl RNA was resolved by SDS–PAGE and analyzed by
western blotting with 0.2 µg/ml anti-TP2 antiserum [12]. The position
of a 116 kDa protein marker is indicated at the right, and that of the
FLAG–TP2 fusion protein is indicated at the left (TP2). The 520-
nucleotide hTR (nucleotides 10–530) [13] was purified from a
genomic hTR PCR product containing a T7 promoter, the antisense
hTR using a T7 primer to the 3′ end of hTR, and the mTR from a
previously described plasmid [5]. Full-length TP2 cDNA containing
sequences encoding the eight amino-acid FLAG epitope [12] was
transcribed and translated using a Promega reticulocyte lysate (TNT)
extract according to the manufacturer’s instructions. RNA preparation
and telomerase assays (TRAP-EZE, Oncor Inc. [24]) were carried out
at the Ontario Cancer Institute.
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added at the onset of transcription and translation of a
full-length TP2 cDNA [12] (Figure 1a, lanes 4–6).
Telomerase activity was not detected in the presence of
either hTR RNA or TP2 protein alone (Figure 1a,
lanes 3,17). TP2 protein in the presence of antisense hTR
(αhTR), transfer RNA (tRNA) or mouse telomerase RNA
(mTR) [15] did not reconstitute telomerase activity
(Figure 1a, lanes 8–16). These results suggest a species-
specific interaction between TP2 and hTR. In the 
micrococcal-nuclease reconstitution of partially purified
human telomerase described by Autexier et al. [14],
activity was also reconstituted with hTR but not mTR.
Western analysis of the lysates using an anti-TP2 anti-
body showed lower TP2 protein levels in the hTR sample
compared with the samples containing inactive RNAs
(Figure 1b), suggesting that the lack of telomerase activ-
ity in the latter samples was not due to lower TP2
protein levels. To rule out the possibility that high TP2
protein levels might inhibit telomerase activity, each
purified RNA was mixed with a constant amount of TP2
that had been translated in a separate reaction, and the
same results were obtained (data not shown). Therefore,
TP2 can reconstitute telomerase activity in reticulocyte
lysates and the reconstituted enzyme shows the same
species-specific interaction with telomerase RNA as that
seen with the native human enzyme [14].
Nucleotides 10–159 of hTR are sufficient for telomerase
activity in vitro
In micrococcal-nuclease-treated human telomerase
extracts, nucleotides 44–204 of hTR are sufficient to
reconstitute telomerase activity, but nucleotides 44–170
are not [14]. We compared the activity of a number of
hTR RNAs, truncated from the 3′ end and lacking the first
nine nucleotides, in the reticulocyte telomerase reconsti-
tution assay (Figure 2a). All truncated RNAs, the shortest
of which consisted of nucleotides 10–159, had detectable
telomerase activity, although the shorter hTR RNAs
showed reduced activity compared with an hTR RNA
consisting of nucleotides 10–354 (Figure 2a). The levels
of TP2 protein in the presence of the truncated RNAs
were higher than in the presence of a 520-nucleotide hTR
(nucleotides 10–530; Figure 2b); higher TP2 levels did
not inhibit the reconstitution, however, because the activ-
ity with the hTR RNA consisting of nucleotides 10–354
was similar to that with the 520-nucleotide hTR. There-
fore, nucleotides 10–159 of hTR are sufficient for telom-
erase activity in this assay. Our ability to detect activity
with a shorter RNA in the reticulocyte lysate assay than
in the micrococcal-nuclease reconstitution assay may
reflect an increased reconstitution efficiency or the
increased sensitivity of the PCR-based telomerase assay
[14]. Therefore, the reconstituted telomerase enzyme
requires a similar region of the hTR RNA as does the
native human telomerase.
hTR and TP2 are the only limiting and necessary
components for activity in vitro
To examine whether hTR and TP2 were the only limiting
components required for activity, we titrated the levels of
hTR and TP2 in the reconstitution system (Figure 3a).
Increasing the amount of telomerase RNA while maintain-
ing a fixed concentration of TP2 cDNA caused a parallel
increase in telomerase activity (Figure 3a, lanes 4–6). Sim-
ilarly, at fixed hTR concentrations, increasing the amount
of TP2 cDNA template in the reaction also resulted in an
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Figure 2
Deletion analysis of hTR in the reconstitution assay. (a) A schematic
representation is shown of the hTR truncations that were tested for the
ability to reconstitute telomerase activity in the presence of full-length
TP2 protein (the boxed region indicates the telomere template). The
numbers refer to the positions of nucleotides within hTR [13].
Lanes 1,2, 5 µg HeLa cell lysate in the absence and presence of
RNAse A; lane 3, TP2 cDNA only; lanes 4–13, TP2 in the presence of
the indicated truncated hTR RNA species (0.01 µg or 0.1 µg RNA per
µl lysate). (b) Each of the in vitro translation mixtures (approximately
2 µl) in (a) containing 0.1 µg/µl of the indicated RNA was analyzed by
western blotting using 0.2 µg/ml anti-TP2 antiserum. The position of
the TP2 protein is indicated at the left, and the protein markers, in kDa,
at the right. The truncated hTR RNAs were generated by digestion of a
520-nucleotide hTR PCR product containing a 5′ T7 promoter
sequence with the following restriction enzymes: nucleotides 10–159,
XbaI; nucleotides 10–205, SmaI, nucleotides 10–258, SacII;
nucleotides 10–354, StuI.
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increase in telomerase activity (Figure 3a, lanes 7–9).
Therefore, both TP2 and hTR are required and are the
limiting components for telomerase activity.
To confirm that the reconstituted activity contained
recombinant TP2 and purified hTR, the recombinant
TP2 protein, which contained a FLAG epitope tag, was
immunoprecipitated from the lysate using an anti-FLAG
antibody. Although FLAG–TP2 was efficiently immuno-
precipitated from the lysates (again, the levels of TP2
protein were lower in the presence of hTR), only the
immunoprecipitates containing FLAG–TP2 and hTR had
telomerase activity (Figure 3b, lanes 6,8). Prior incuba-
tion of the antibody with a FLAG peptide, which had
the effect of preventing FLAG–TP2 immunoprecipita-
tion, did not result in immunoprecipitation of telomerase
activity (Figure 3b, lane 7), whereas a non-specific
peptide had no effect (Figure 3b, lane 8). Reverse tran-
scription and PCR analysis of the immunoprecipitated
material showed that hTR was associated with
FLAG–TP2 and telomerase activity (Figure 3b,
lanes 6,8). Thus, the telomerase activity observed resides
in a complex that contains recombinant human TP2 and
hTR. Although we cannot exclude the possibility that
other rabbit proteins in the lysate contribute to the activ-
ity, we examined the lysates and immunoprecipitates
using polyclonal antibodies against the telomerase-asso-
ciated protein TP1/TLP1 (encoded by the TEP1 gene
[5,6]), and we did not detect a cross-reactive species.
To determine whether the reverse transcriptase domain
of TP2 was essential for telomerase activity in vitro, we
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TP2 and hTR are limiting and necessary for telomerase activity in vitro.
(a) Results of telomerase assays. Lanes 1,2, 5 µg HeLa cell lysate in
the absence and presence of RNAse A; lane 3, TP2 cDNA only (0.1 µg
cDNA in a 10 µl transcription–translation reaction); lanes 4–6, 0.02 µg
full-length TP2 cDNA (in 50 µl reticulocyte lysate) translated in the
presence of 0.001 µg, 0.005 µg or 0.01 µg hTR RNA per µl lysate;
lanes 7–9, increasing amounts of TP2 cDNA (0.01 µg, 0.02 µg, or
0.05 µg in 50 µl reticulocyte lysate) translated in the presence of
0.002 µg/ µl hTR in the lysate. (b) The reticulocyte lysate
(approximately 10 µl) containing TP2 only (0.5 µg, lane 1) or TP2 and
hTR (0.5 µg TP2 cDNA and 0.5 µg hTR in a 50 µl
transcription–translation reaction, lane 2) was immunoprecipitated
using 10 µl agarose beads containing anti-FLAG antibody (Kodak),
washed, and then analyzed for telomerase activity (upper panel), or
subjected to western blot analysis using 0.2 µg/ml anti-TP2 antiserum
(middle panel) or reverse transcription (RT)-PCR analysis using hTR-
specific primers (lower panel). The immunoprecipitations were carried
out with no competing peptide (lanes 3,6), a specific peptide (FLAG,
lanes 4,7), or a non-specific peptide derived from TP1 [5] (NS,
lanes 5,8). In the lower panel, as controls, the RT-PCR was carried out
in the absence (–) or presence (+) of hTR RNA. The slightly smaller
species detected by RT-PCR in lanes 1 and 2 (indicated by asterisk) is
not specific for the hTR primers. (c) Effect of TP2 point mutations on
telomerase activity. Lane 1, wild-type TP2 cDNA (0.5 µg in a 50 µl
reticulocyte lysate reaction containing 0.1 µg/µl hTR RNA); lanes 2–5,
TP2 cDNAs carrying the indicated point mutation (0.5 µg in a 50 µl
reticulocyte lysate reaction containing 0.1 µg/µl hTR); lane 6, no cDNA
template added. In the lower panel, each of the in vitro translation
mixtures (approximately 2 µl) in (a) was analyzed by western blotting
using 0.2 µg/ml anti-TP2 antiserum. The positions of protein markers
are shown at the right and the position of full-length TP2 is indicated at
the left. TP2 cDNAs carrying point mutations were transcribed and
translated as described for wild-type, FLAG-tagged TP2 in the legend
to Figure 1.
introduced point mutations in sequences encoding con-
served aspartate residues within the reverse transcriptase
domain of TP2 [12]. Mutant TP2 proteins were pro-
duced which carried the single amino acid substitutions
D868A, D869A and D712A, and the double substitution
D868A,D869A (using the single-letter amino-acid code).
We showed previously that each of these point mutations
severely decrease telomerase activity associated with
transfected, recombinant TP2 in human cell lysates [12].
Reticulocyte lysates supplied with wild-type TP2 and
hTR contained telomerase activity (Figure 3c, lane 1),
however the point mutated forms of TP2 could not
reconstitute activity (Figure 3c, lanes 2–5). Although the
levels of mutant TP2 proteins were higher than the level
of wild-type TP2 (Figure 3c, lower panel), similar results
were also obtained when the proteins were first trans-
lated and equal amounts mixed with purified hTR. The
fact that telomerase activity is completely abolished only
when mutant TP2 protein is present shows that a func-
tional reverse transcriptase domain within TP2 is essen-
tial for catalytic activity. In yeast, the introduction of
these analagous mutations in the reverse transcriptase
domain of the TP2 homolog Est2 completely abolishes
telomerase activity in crude cell lysates [8,16].
In yeast, the telomerase RNA TLC1 and the Est1, Est2,
Est3, and Est4/Cdc13 proteins are each essential for
maintenance of telomere length in vivo [17–19], but only
Est2 and TLC1 are essential for telomerase activity in cell
lysates [8,20,21]. Despite the known association of
telomerase activity with other protein subunits in vivo,
such as TP1/TLP1 [5,6], human telomerase might
contain only two essential components — TP2 and hTR.
Further purification of the reconstituted enzyme will be
required to rule out the contribution of other reticulocyte
proteins to telomerase activity. The reticulocyte-lysate
telomerase-reconstitution system described here will be
useful in further elucidating the role of TP2 and other
associated proteins in telomerase function, such as elon-
gation, processivity, telomerase RNA binding and telom-
eric primer recognition.
Recently, the reconstitution of human telomerase activity
in reticulocyte lysates and in human cell lines with recom-
binant TRT1 was reported by Weinrich et al. [22] and
Nakayama et al. [23]. The gene symbol TP2 is provisional
and the allocation of an official gene symbol is currently
under consideration by the Human Genome Organization
nomenclature committee. 
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